Provided by Tiger Trade Technology Pte. Ltd.

LAEKNA-B

12.400
-1.110-8.22%
Volume:2.87M
Turnover:36.66M
Market Cap:5.53B
PE:-17.44
High:13.510
Open:13.510
Low:12.370
Close:13.510
52wk High:23.500
52wk Low:8.100
Shares:446.00M
HK Float Shares:446.00M
Volume Ratio:1.84
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.711
ROE:-34.59%
ROA:-19.92%
PB:6.88
PE(LYR):-17.44
PS:1060.64

Loading ...

Laekna, Inc. (02105) Announces January 2026 Monthly Return on Movements in Securities

Bulletin Express
·
Feb 05

An Insider At Laekna Lowered Their Holding Recently

Simply Wall St.
·
Jan 25

LAEKNA-B (02105) Surges Nearly 5% in Afternoon Trading as US FDA Accepts LAE118 New Drug Clinical Trial Application

Stock News
·
Jan 16

LAEKNA-B (02105) Rises Nearly 7% as FDA Accepts IND Application for New Drug LAE118

Stock News
·
Jan 14

LAEKNA-B (02105): US FDA Accepts LAE118 New Drug Clinical Trial Application

Stock News
·
Jan 14

FDA Accepts Investigational New Drug Application for Laekna LAE118

Reuters
·
Jan 14

Laekna Doses Subject in LAE103 Study

MT Newswires Live
·
Dec 31, 2025

LAEKNA-B (02105) Completes First Patient Dosing in Phase I Single Ascending Dose Study for LAE103

Stock News
·
Dec 31, 2025

Laekna Inc. Doses First Subject in Phase I Trial of LAE103 for Obesity and Metabolic Diseases

Reuters
·
Dec 31, 2025

Laekna Doses First Patinet in Weight Drug Study

MT Newswires Live
·
Dec 22, 2025

LAEKNA-B (02105): First Patient Dosed in Phase I Multiple-Dose Expansion Study of LAE102 for Obesity Treatment

Stock News
·
Dec 22, 2025

Laekna Inc. Begins Phase I Multiple Dose Study of LAE102 for Obesity Treatment

Reuters
·
Dec 22, 2025

Laekna Completes Patient Enrollment In LAE002 Breast Cancer Study

MT Newswires Live
·
Dec 15, 2025

LAEKNA-B (02105): Enrollment Completed for Phase III Clinical Trial (AFFIRM-205) of LAE002 (Afuresertib) in HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Stock News
·
Dec 15, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Dec 12, 2025

LAEKNA-B (02105): Xie Ling and Zhou Jian Appointed as Members of Nomination and Corporate Governance Committee

Stock News
·
Dec 12, 2025

Laekna Inc. Files Director List with HKEX

Reuters
·
Dec 12, 2025

Laekna Inc. Appoints Xie Ling and Zhou Jian to Nomination and Corporate Governance Committee

Reuters
·
Dec 12, 2025

HK Stock Movement | LAEKNA-B (02105) Rises Over 5% in Early Trading, LAE002 Expected to Submit NDA in First Half of 2026

Stock News
·
Dec 04, 2025

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

Stock News
·
Dec 03, 2025